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Disease and Polygenic Architecture: Avoid
Trio Design and Appropriately Account
for Unscreened Control Subjects for Common Disease
Wouter J. Peyrot,1,2,* Dorret I. Boomsma,3 Brenda W.J.H. Penninx,1 and Naomi R. Wray2,*
Genome-wide association studies (GWASs) are an optimal design for discovery of disease risk loci for diseases whose underlying genetic
architecture includes many common causal loci of small effect (a polygenic architecture). We consider two designs that deserve careful
consideration if the true underlying genetic architecture of the trait is polygenic: parent-offspring trios and unscreened control subjects.
We assess these designs in terms of quantification of the total contribution of genome-wide genetic markers to disease risk (SNP herita-
bility) and power to detect an associated risk allele. First, we show that trio designs should be avoided when: (1) the disease has a lifetime
risk > 1%; (2) trio probands are ascertained from families with more than one affected sibling under which scenario the SNP heritability
can drop by more than 50% and power can drop as much as from 0.9 to 0.15 for a sample of 20,000 subjects; or (3) assortative mating
occurs (spouse correlation of the underlying liability to the disorder), which decreases the SNP heritability but not the power to detect a
single locus in the trio design. Some studies use unscreened rather than screened control subjects because these can be easier to collect;
we show that the estimated SNP heritability should then be scaled by dividing by (1  K 3 u)2 for disorders with population prevalence
K and proportion of unscreened control subjects u. When omitting to scale appropriately, the SNP heritability of, for example, major
depressive disorder (K ¼ 0.15) would be underestimated by 28% when none of the control subjects are screened.Optimal experimental design of genetic studies of disease
for discovery of associated loci depends on the underlying
genetic architecture of the trait. Although the true genetic
architecture of the trait is usually not known, different
experimental designs aim at exposing causal loci of
differing population frequencies. For example, the optimal
experimental design to detect de novo mutations is a trio
design in which affected probands and their parents are
genotyped.1 In contrast, genome-wide association studies
(GWASs) are an optimal design for a genetic architecture
that includes many common causal loci of small effect
(a polygenic architecture). Here, we consider two designs
of GWASs, which we show deserve careful consideration:
designs based on parent-offspring trios and designs based
on unscreened control subjects. We assess these designs
in terms of quantification of the total contribution to dis-
ease risk of genome-wide genetic markers, via estimation
of so-called SNP heritability,2 and the power to detect an
associated risk allele.
Our study is motivated by experiences with GWAS de-
signs for psychiatric disorders, but our results are parame-
terized based on baseline disease risk and heritability, and
are, therefore, applicable to the full range of diseases and
disorders with a polygenic genetic architecture of underly-
ing risk. For psychiatric disorders, GWASs have had vari-
able success in detecting genome-wide significant com-
mon SNPs. On the one hand, 108 significant loci were
recently found for schizophrenia (SCZ [MIM: 181500]) in
a sample comprising 36,989 case subjects,3 whereas only
two loci were found in one study on major depressive dis-
order (MDD [MIM: 608516])4 but none in another,5 no loci1Department of Psychiatry, VU University Medical Center & GGZ inGeest, Am
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143465]),6 and only single-study genome-wide significant
loci for autism spectrum disorder (ASD [MIM: 209850]).7–9
Sample size is pivotal in explaining this discrepancy,
because much smaller numbers of cases were included for
MDD (5,303 and 9,240, respectively), ADHD (2,960), and
ASD (2,705, 1,984, and 1,553, respectively) than for SCZ.
Other contributing factors have, nevertheless, been pro-
posed, such as the impact of de novo mutations in
ASD10,11 (although these are expected to explain only a
small proportion of variation),12 lower family-based herita-
bility of MDD (~0.4 versus ~0.8 for SCZ, ASD, and ADHD,
assuming a similar genetic architecture between disor-
ders),13 and higher prevalence and greater heterogeneity
of MDD.14 Here, we show that the trio design, which is
regularly applied in ASD and ADHD, and use of unscreened
control subjects deserves careful consideration in the
context of an underlying polygenic architecture, which is
an important consideration for design of future studies
that strive to increase sample size.15
The impact of trio design and the use of unscreened con-
trol subjects on the SNP heritability have, to the best of our
knowledge, not yet been described, probably because the
methods for estimation of SNP heritability were developed
only in recent years.16,17 The impact on the power to
detect a single locus has, on the other hand, been studied
in the pre-GWAS era of candidate genes,18–21 but we could
find no clear-cut comparison of the power to detect an
associated risk allele with trio studies versus screened con-
trol studies, and we will therefore also give an overview of
these differences. We investigate the trio design and thesterdam 1081 HL, the Netherlands; 2Queensland Brain Institute, University
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use of unscreened control subjects by analytical derivation
followed by simulation studies to validate theory. Assorta-
tive mating (correlation in liability between spouses) is
included in our trio design analyses, because this has
been reported for a range of psychiatric disorders.22–25
For example, a spouse correlation on the social responsive-
ness scale (a quantitative measure of autistic traits) of 0.29
has been reported in a population sample23 and of 0.26 in
parents of ASD probands.22 For ADHD a spouse correlation
of 0.11 on the ADHD index in population samples has
been reported.25 In trio designs, genotypes of proband
cases are compared to genotypes of pseudocontrol subjects
(the non-transmitted parental alleles).SNP Heritability Calculations
The SNP heritability estimates the total proportion of vari-
ance tagged by common SNPs from a genome-wide associ-
ation study.2,16 If samples with GWAS data are population
samples, then the variance estimated on the observed scale
ðbh2oÞ is expressed with the Robertson’s transformation on
the liability scale ðbh2l Þ as26
bh2l ¼ bh2oKð1 KÞz2 ; (Equation 1)
where z denotes the height of the standard normal density
function at the threshold corresponding to a baseline dis-
ease risk K. Quantification on the liability scale is most
interpretable because it allows direct comparisons of esti-
mates of heritability from family data that are reported
on this scale to estimates of variance explained by individ-
ual genome-wide significant loci. However, usually GWAS
samples are oversampled for case subjects compared to
population samples and the transformation of proportion
of variance attributable to SNPs estimated from case-con-
trol data ðbh2occÞ must also account for the proportion of
cases in the sample P by2,27
bh2l ¼ bh2occK2ð1 KÞ2Pð1 PÞz2 ; (Equation 2)
which reduces to Equation 1 when the sample is
a population sample and P ¼ K. However, these trans-
formations assume that control subjects are screened.
To account for control subjects being unscreened,
we define F as the proportion of falsely classified
control subjects, F¼Nfalse controls=ðNfalse controlsþNtrue controlsÞ¼
Nfalse controls= Ncontrols. We closely followed the derivations of
Golan et al. (paragraphs 1.2 and 1.3 of their Supplemental
Materials)27 to derive an updated equation (Table S1)
validated by simulation (Table S2),
bh2l ¼ bh2occ K2ð1 KÞ2
Pð1 PÞð1 FÞ2z2; (Equation 3)
which reduces to Equation 2 when F ¼ 0 and control sub-
jects are screened. If a proportion u of the control subjects
are a random sample from the population, then one canThe Americassume that F z Ku. Therefore, if it is unknown whether
control subjects are screened or not, the potential underes-
timation when all control subjects are unscreened (u ¼ 1)
of the SNP heritability bh2l estimated from the standard
Equation 2 can be assessed as bh2l ð1 KÞ2 and thus depends
on baseline risk K. In trio designs where probands are ascer-
tained randomly, the pseudocontrol subjects are equiva-
lent to unscreened control subjects under a polygenic
model (Figure S1).
For the trio design, the SNP heritability was derived for
a disease parameterized with normally distributed pheno-
typic (l) and genetic (G) liabilities with means E(l) ¼
E(G) ¼ 0 and variances Vl ¼ 1 and VG ¼ h2l , the true her-
itability on the liability scale in the parental generation.28
Under the liability-threshold model, individuals are
deemed affected when their liability (l) is larger than
threshold (T) such that Pðl > T j l  Nð0;1ÞÞ ¼ K. Parental
assortative mating was taken into account by parameter-
izing a spouse liability correlation of rl and genetic corre-
lation of rG ¼ h2l rl.28 The E(G) of proband case subjects
and pseudocontrol subjects were derived by considering
the variance-covariance matrix of l and G of individuals
that could contribute to a trio design (proband, sibling,
mother, father, pseudocontrol). To account for the
affected proband, the variance-covariance matrix of
random families was conditioned on the proband being
affected by accounting for the reduction in variance as a
result of the Bulmer effect29 in related individuals
described by Tallis.30 To account for a second affected sib-
ling, the variance-covariance matrix was further condi-
tioned on the sibling also being affected. Details of these
derivations are provided in the Supplemental Methods
and were validated with a simulation study in R (Tables
S3 and S4).
Figure 1A displays the SNP heritability assessed from un-
screened control subjects (Figure 1A, dashed line), which
is equivalent to estimates from pseudocontrol subjects
from random families with at least one affected proband
(Figure 1A, dotted line) and screened control subjects
(Figure 1, solid lines). Although the standard transforma-
tion (Equation 2) applied to derive estimates of SNP herita-
bility on the liability scale ðbh2l Þ is expected to give unbiased
estimates of the true SNP heritability when case subjects
are randomly ascertained and control subjects are screened
(Figure 1A, solid line), the transformation underestimates
h2l by a factor (1  K)2 when diseases are common (high
K) and control subjects are unscreened or are pseudocon-
trol subjects (Figure 1A, dashed and dotted line). The esti-
mated heritability from the Equation 2 transformation bh2l
severely underestimates h2l when data result from a trio
design with probands ascertained from multiplex families
(Figure 1B, dotted line), for example, bh2l ¼ 0:31 for K ¼
0.05 and h2l ¼ 0:5, because the mean liability of pseudo-
control subjects is greater than the average in the popula-
tion and so the contrast in genetic values between case sub-
jects and pseudocontrol subjects is less than between case
subjects and screened control subjects (Table 1, additionalan Journal of Human Genetics 98, 382–391, February 4, 2016 383
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Figure 1. Relationship between the True SNP Heritability and Its Estimates Based on the Standard Transformation with Equation 2
from Trio Data, Screened Controls, and Unscreened Controls
The SNP heritability bh2l that would be estimated based on the standard liability transformation equation (Equation 2) for GWASs using
pseudocontrol subjects (dotted lines), unscreened control subjects (dashed lines), and screened control subjects (solid lines) compared
to the true parental SNP heritability h2l for designs based on randomly ascertained proband families (A), families with an additional
affected sibling (B), in the context of parental assortative mating with a correlation on the liability scale of rl ¼ 0.3 (C), and families
with an additional affected sibling in the context of parental assortative mating (D) for disorders with lifetime risk K ¼ 0.01, 0.05,
and 0.15. The pseudocontrol subjects of randomproband families are equivalent to unscreened control subjects (dashed and dotted lines
overlap in A), and the slope of these lines are defined by (1  K)2, i.e., the underestimation of bh2l when mistakenly applying Equation 2
rather than Equation 3 to transform the heritability on the observed scale to the liability scale when none of the control subjects are
screened.
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Table 1. Mean Genetic Liabilities and SNP Heritability Estimated from the Standard Transformation with Equation 2 from GWAS using
Trio Design, Screened Control Subjects, or Unscreened Control Subjects for Actual Parental Heritability 0.5
K h2l Parents
Mean Genetic Liability (E(G))
bh2l Assessed from Proband
Case
Control
Screened Unscreened Pseudo Screened Unscreened Pseudo
Random Proband Families
0.01 0.5 1.333 0.013 0.000 0.000 0.500 0.490 0.490
0.05 0.5 1.031 0.054 0.000 0.000 0.500 0.451 0.451
0.15 0.5 0.777 0.137 0.000 0.000 0.500 0.361 0.361
Additional Sibling Affected
0.01 0.5 1.634 0.013 0.000 0.543 0.749 0.736 0.328
0.05 0.5 1.275 0.054 0.000 0.424 0.750 0.690 0.307
0.15 0.5 0.972 0.137 0.000 0.323 0.735 0.565 0.251
Parental Assortative Mating
0.01 0.5 1.386 0.016 0.000 0.097 0.542 0.530 0.459
0.05 0.5 1.075 0.060 0.000 0.075 0.547 0.490 0.424
0.15 0.5 0.812 0.148 0.000 0.057 0.552 0.395 0.341
Additional Sibling Affected and Parental Assortative Mating
0.01 0.5 1.706 0.016 0.000 0.670 0.818 0.803 0.296
0.05 0.5 1.335 0.060 0.000 0.525 0.826 0.756 0.278
0.15 0.5 1.021 0.148 0.000 0.402 0.818 0.624 0.230
The mean genetic liabilities E(G) are displayed for probands, unrelated screened control subjects, unrelated unscreened control subjects, and their pseudocontrol
subjects as well as the SNP heritability bh2l estimated from Equation 2 from comparing case subjects to these three sets of control subjects, for different parame-
terization of baseline disease risk K and a fixed underlying heritability of h2l ¼ 0:5. The probands are parameterized in line with Figure 1 to be selected from random
proband families (Figure 1A), families with an additional affected sibling (Figure 1B), families in the context of parental assortative mating (Figure 1C), and families
with an additional affected sibling in the context of assortative mating (Figure 1D), respectively.sibling affected), which is not fully compensated by the
fact that case subjects from multiplex families have higher
mean liability than randomly selected case subjects
(Table 1, random proband families). In contrast, when
case subjects are selected from multiplex families and con-
trol subjects are screened, the estimated SNP heritability
based on the standard transformation is an overestimate
of h2l (for example,
bh2l ¼ 0:75 for K ¼ 0.05 and h2l ¼ 0:5).
When control subjects are unscreened, the SNP heritability
is found between the SNP heritabilities from screened and
pseudocontrol subjects (Figure 1, dashed lines), when SNP
heritabilities are estimated by Equation 2. In the context of
assortative mating, a trio design comparison of probands
to pseudocontrol subjects yields decreased bh2l (Figure 1C;
Table 1, parental assortative mating; spouse correlation
rl ¼ 0.3). Again, comparing the probands to screened
control subjects (from the offspring generation) does in
fact overestimate the heritability in the parent generation
h2l ; this is, however, a well-known consequence of assorta-
tive mating and is not restricted to the trio design
ðVG;offspring ¼ VG;parents þ ð1=2ÞrG;parentsVG;parentsÞ.29 The most
pronounced difference between screened and pseudocon-
trol control subjects is found for probands with an addi-
tional affected sibling in the context of parental assortativeThe Americmating (Figure 1D; Table 1, additional sibling affected and
parental assortative mating).
Power Calculations
The power to detect an associated risk allele in a case-con-
trol association test follows from the non-centrality param-
eter NCP of the c2 test statistic. This NCP is expressed in
terms of sample size N, proportion of case subjects in the
study v, the allele frequency in case subjects pcase, the allele
frequency in control subjects pcontrol, and the mean allele
frequency in the sample p ¼ vpcase þ ð1 vÞpcontrol as
NCP ¼

pcase  pcontrol
2
pð1 pÞ

1
2Nv þ 12Nð1vÞ
 (Equation 4)
and the power as Pð x > ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃNCPp þ xT  z  Nð0;1ÞÞ, where
xT is the z -value quantile-function of the standard normal
distribution for the desired significance threshold, here set
at a¼ 53 108 (xT¼5.45). The power of different experi-
mental designs is reflected in the appropriate expressions of
pcase and pcontrol. We parameterize a disease with a baseline
lifetime disease risk K, a di-allelic locus with risk allele fre-
quency P(B) ¼ p, non-risk allele frequency P(b) ¼ q ¼ 1  p,an Journal of Human Genetics 98, 382–391, February 4, 2016 385
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Figure 2. Power to Detect a Single Risk Variant in Association Studies of 10,000 Case Subjects that Use a Trio Design, Screened Con-
trol Subjects, or Unscreened Control Subjects
Power of association analysis comparing 10,000 probands to 10,000 screened control subjects (solid line), 10,000 unscreened control
subjects (dashed), 20,000 unscreened control subjects (dot-dashed), and 10,000 pseudocontrol subjects (dotted) to detect a single asso-
ciated risk variant for a risk allele with frequency p¼ 0.2, for a baseline disease risk K¼ 0.01, 0.05, and 0.15. Power was estimated for risk
variants with underlying additive effect ðRRBB ¼ RR2BbÞ for random ascertainment of probands (A) and probands from families with an
additional affected sibling (B). Note that pseudocontrol subjects from random families are equivalent to unscreened control subjects
and that the dotted and dashed lines in (A) overlap. The variation explained on the liability scale was approximated by
h2locusz2pð1 pÞðRRBb  1Þ2=i2, where i equals z/K the mean liability of probands, and z the height of the standard normal density func-
tion at the threshold corresponding with disease of lifetime risk K.relative risk of heterozygotes RRBb ¼ PðDisease jBbÞ=
PðDisease j bbÞ, and relative risk of the homozygotes
RRBB ¼ PðDisease jBBÞ=PðDisease j bbÞ.31,32 When control
subjects are screened, power follows from pcase ¼
kbbRRBbp(1 þ p(RRBb  1))/K, where kbb ¼ PðDisease jbbÞ ¼
K=ðq2 þ 2pqRRBb þ p2RRBBÞ and pcontrol ¼ ((1  kbbRRBb)
p(1  p) þ (1  kbbRRBB)p2)/(1  K),32 which agrees with
the genetic power calculator of Purcell et al.33When control
subjects are unscreened, the power of an association study is
expressed by Equation 4 with pcontrol¼ p. For the trio design,
power was assessed by substituting in Equation 4 the allele
frequency in probands and pseudocontrol subjects (the
non-transmitted alleles of theparents).When trios are ascer-
tained from families with an additional affected sibling or
when there is assortative mating, the risk allele frequency
in control subjects can be derived from combined and con-
ditional genotype frequencies of an individual, the affected
sibling, and the parents. Under assortative mating, expres-
sions are dependent on spouse liability correlation rliability,
which results in the correlation between the parental geno-
types as rlocus ¼ rliabilityh2locus.28 It follows that assortativemat-
ing (for example, rliability¼ 0.3) has no impact on the power
to detect a single locus for loci typical of polygenic architec-
ture that explain less than 1% of variation (rlocus ¼ 0.3 3386 The American Journal of Human Genetics 98, 382–391, February0.01 ¼ 0.003).28 When assuming a small RRBb typical of
complex genetic disease and a multiplicative model on the
disease scale (RRBB ¼ RR2Bb, implying additively on the un-
derlying risk scale), the variance attributable to the risk locus
can be approximated by h2locusz2pqðRRBb  1Þ2=i2 with i ¼
z/K the mean liability of case subjects and z the height of
the standardnormal density functionat the threshold corre-
sponding to a baseline disease risk K.32 The expressions to
derive allele frequencies in trios are closed but complex
(Supplemental Methods) and were validated by simulation
(Table S5).
Figure 2 displays the power to detect an associated risk
allele for probands from random trios with an affected pro-
band (Figure 2A) and multiplex trios with an additional
affected sibling (Figure 2B), when the risk allele has a fre-
quency of P(B) ¼ p ¼ 0.2 for disorders with baseline risk
K ¼ 0.01, 0.05, and 0.15 in a sample of n ¼ 10,000 trios
(probands versus pseudcontrol subjects) against RRBb given
an underlying additive effect ðRRBB ¼ RR2BbÞ (dotted line).
Note that pseudocontrol subjects from random families
are equivalent to unscreened control subjects (Figure S1),
which are displayed in Figure 2 for 10,000 unscreened con-
trol subjects (dashed line) and 20,000 unscreened control
subjects (dot-dashed line) compared to 10,000 probands.4, 2016
Table 2. Maximum Power Difference between Trio Design and Screened Control Subject Studies with 20,000 Subjects
K RRBb
Allele Frequencies Power (n ¼ 20,000) n (Power ¼ 0.8)
Proband Pseudo Screened Pseudo Screened Pseudo Screened
Proband from Random Proband Families
0.01 1.147 0.223 0.200 0.200 0.56 0.58 25,226 24,714
0.05 1.144 0.222 0.200 0.199 0.51 0.63 26,327 23,712
0.15 1.135 0.221 0.200 0.196 0.39 0.74 29,670 21,297
Proband from Families with an Additional Affected Sibling
0.01 1.115 0.228 0.209 0.200 0.17 0.91 39,201 17,307
0.05 1.113 0.227 0.209 0.199 0.15 0.92 40,533 16,923
0.15 1.108 0.226 0.208 0.197 0.11 0.94 44,574 15,945
The loci with allele frequency p¼ 0.2 from Figure 2 that result in most pronounced decrease in power for pseudocontrol compared to screened control studies for a
sample of 10,000 case subjects and 10,000 control subjects are displayed in detail. The power difference depends on the baseline disease risk K, its effect size RRBb,
and whether the probands are from random proband families or families with an additional affected sibling (compare to solid and dotted lines, respectively,
in Figure 2). For these loci, the allele frequencies in probands, pseudocontrol subjects, and screened control subjects is displayed, as well as the power given a
sample size of n ¼ 20,000 (50% case subjects) and the required sample size to obtain a power of 0.8. Note that pseudocontrol subjects from random families
are equivalent to unscreened population control subjects.The solid line on each graph is the power for 10,000 pro-
bands compared to 10,000 unrelated screened control sub-
jects. Figure 2A shows that there is little to be gained in
screening control subjects for diseases of lifetime morbid
risk < 1%, but for more common disorders (such as
ADHD and MDD), there is an important gain in power,
which can also be gained by increasing the number of un-
screened control subjects. When trios come from families
with an additional affected sibling, the case subjects have
an increased probability of carrying the risk allele and so
when matched with screened control subjects, there is a
gain in power compared to random ascertainment of case
subjects (solid line in Figure 2B versus solid line in
Figure 2A). For example, when p ¼ 0.2, RRBb ¼ 1.2, then
pproband B ¼ 0.248 and pproband A ¼ 0.231, respectively
(these frequencies do not depend on K). However, when
the association study is of case subjects from multiplex
families compared to pseudocontrol subjects, there is little
gain in power compared to trios based on randomly
selected case subjects (dotted line in Figure 2B versus
dotted line in Figure 2A), because the pseudocontrol sub-
jects also have increased probability of carrying the risk
allele (ppseudocontrol B ¼ 0.215 and ppseudocontrol A ¼ 0.2). The
maximum power difference between using screened and
pseudocontrol subjects depends on RRBb, K, sample size,
and whether probands are ascertained randomly or from
families with an additional affected sibling (Table 2),
but is found for a sample comprising 20,000 subjects at
RRBb ¼ 1.11 and K ¼ 0.15 for probands with additional
affected siblings, under which scenario a total sample
size of n ¼ 15,945 is needed when control subjects are
screened versus n ¼ 44,574 for the pseudocontrol trio
design, respectively, to obtain a power of 0.8. For un-
screened control subjects (equivalent to pseudocontrol
subjects from random families), the most pronounced
decrease in power in a sample of 20,000 subjects is foundThe Americfor a locus with RRBb ¼ 1.14 in disease with K ¼ 0.15 where
unscreened control subjects yield a power of 0.39 and
screened control subjects a power of 0.74. As expected,
the impact of using screened control subjects is higher
for more common disorders. Allele frequencies in pro-
bands, pseudocontrol subjects, and screened control sub-
jects for all Figure 2 scenarios are presented in Figure S2.
Furthermore, the power differences between pseudocon-
trol and screened control studies are consistent for other
risk allele frequencies, e.g., p ¼ 0.6 (Figure S3) underlying
actual recessive (RRBb ¼ 1; Figure S4) and dominant
(RRBb ¼ RRBB; Figure S5) effects. In addition, to select
only trios with unaffected parents has no impact on power
of pseudocontrol studies, because although the risk allele
frequency in pseudocontrol subjects decreases, the fre-
quency in case subjects decreases proportionally
(Figure S6). When unscreened control subjects are much
easier to obtain then screened control subjects, the loss
of power due to not screening can be balanced by
increasing the number of unscreened control subjects,
which is illustrated for different numbers of unscreened
control subjects in Figure S7. Note that Equation 4 defines
a limit to the power-gain from increasing the number of
unscreened control subjects, but that when increasing
number of unscreened control subjects from 10,000 to
20,000, the loss of power due to not screening is balanced
for all scenarios under consideration here. In Figure 2,
the additional x axis is variance explained by the locus,
and therefore the results generalize to many combinations
of p and RRBb that together explain the same locus vari-
ance.31 Although association studies have similar power
to detect a locus based on RRBb regardless of baseline dis-
ease risk K, the variance explained by a locus is much larger
for high K. Therefore, to detect a risk allele that explains
the same proportion of genetic variance, a much larger
sample size is needed for larger K (Figure 3).an Journal of Human Genetics 98, 382–391, February 4, 2016 387
Figure 3. Power to Detect an Associated Locus by the Propor-
tion of Variation It Explains
The power to detect an associated locus depends on the propor-
tion of variation it explains on the liability scale h2locus, the baseline
disease risk K, and is displayed for random case versus screened
control. For a locus with the same h2locus, larger sample sizes are
required for larger K. h2locus can be approximated by 2p(1  p)
(RRBb  1)2/i2, where i equals z/K the mean liability of probands,
and z the height of the standard normal density function at the
threshold corresponding with disease of lifetime risk K. The (com-
plex) relation between allele frequency p, RRBb, and the non-cen-
trality parameter NCP given h2locus results in an identical relation
between power and h2locus for varying p.To summarize our findings, our results generate two
important conclusions that trio-based samples and un-
screened control subjects for common diseases deserve
careful consideration when the underlying genetic archi-
tecture is highly polygenic. We have quantified this in
two ways, first by the underestimation of SNP heritability
through application of the inappropriate transformation
equation, and second by power calculations of association
analysis. We derived a transformation equation for the
SNP heritability that is appropriate for unscreened control
samples (Equation 3).
The use of trio designsmost commonly occurs for pediat-
ric diseases and disorders in which it is relatively easy to
obtain blood samples fromparents. Trio designs are needed
to detect de novo causal mutations,34 to determine accu-
rately phased haplotypes,34 and to undertake parent-of-
origin analyses implied by a hypothesis of parental
imprinting.35 Trio designs have also been considered for
detection of gene-environment interaction.36,37 In the
pre-GWAS era, trio designs were recommended to protect
against potential bias from population stratification,1 and
although this quality is also sometimes promoted for trio
GWAS, with genome-wide SNP data, other strategies, such
as genomic principal components38 ormixedmodel associ-
ationanalysis,39 appropriately account for population strat-
ification without the need to incur 50% higher costs by
genotyping three samples to generate two genomes. While
acknowledging the benefits of parent-offspring trios under
some experimental paradigms, trio-design GWASs have
been undertaken without full regard of the implications388 The American Journal of Human Genetics 98, 382–391, Februaryto power under the genetic architecture implicated by the
GWAS paradigm. We draw the following conclusions.
(1) If the case probands of trios are ascertained
randomly, then the resulting case-pseudocontrol
study is equivalent to a case-unscreened control
design under a polygenic genetic architecture and
has little impact on the SNP heritability and power
for disorders that are less common, but for more
common disorders there is important decrease in
SNP heritability (Figure 1A) and loss of power
(Figure 2A), inadvertently contributing to the
missing heritability problem. For example, in a
study on MDD (lifetime risk K ~ 0.15)13,40 where
all control subjects are unscreened, the SNP herita-
bility (say 0.3) would reduce by a factor of 0.72
(0.72 3 0.3 ¼ 0.22) (hence underestimated by
28%) when not accounting for the unscreened con-
trol subjects (i.e., applying Equation 2 rather than
Equation 3). For disorders such as MDD, even
when control subjects have been screened, it is
likely that some control subjects remain misclassi-
fied, because onset can occur throughout the life-
time. Naturally, it should also be noted that when
super-control subjects are used (control subjects
screened to be at the lower end of the liability distri-
bution, for example based on low scores for the per-
sonality trait neuroticism in the context of MDD),
SNP heritability estimates based on the standard
transformation equation would be biased upward.
The loss of power due to including unscreened con-
trol subjects can be compensated by increasing
the number of control subjects (Figures 2 and S7),
in particular in the context of the continuously
decreasing costs for genotyping, but this requires
caution when estimating the SNP heritability,
because Equation 3 should then be applied rather
than the standard Equation 2.
(2) If case probands are ascertained from multiplex
families, then the SNP heritability and power of
GWASs are substantially reduced when using pseu-
docontrol subjects even for less-common disorders
(see Figures 1B and 2B, respectively; modeled on
families with two affected siblings). Even in the
absence of deliberate ascertainment of multiplex
families, studies are likely to be biased by self-ascer-
tainment because parents from multiplex families
might be more concerned with the genetic origins
of the disorder. In fact, 43.6% of the 1,369 families
included in the Autism Genome Project (AGP) had
two or more children affected with ASD while
counting up to third-degree relatives.7 However,
the proportion of multiplex families is often not
reported, as is the case for the family-based
studies,41–43 contributing to the most recent
ADHD meta-analysis,6 which leaves the loss in po-
wer due to included multiplex families unknown,4, 2016
but likely. In addition, in a number of families with
a first affected child, parents will stop having chil-
dren, so that a second affected child is never
observed. Our results are consistent with the sim-
plex versus multiplex and simulation results of
Klei et al. in analyses of ASD samples.44
(3) Assortative mating considerably decreases the SNP
heritability assessed from trio design compared
to screened control subjects also for small K
(Figure 1C), but it does not impact the power to
detect a single locus under a polygenic model,
because of the small proportions of variation ex-
plained by single loci (<1%). Assortative mating is
possibly common for psychiatric disorders22–25
and needs to be considered when interpreting SNP
heritability in general and for trio design in partic-
ular. These results and point (2) could explain why
lower SNP-based heritabilities were found in the
ADHD pseudocontrol samples from the Psychiatric
Genomics Consortium compared to case-control
samples (see Table S5 of Lee et al.).14
We also take the opportunity to re-emphasize that
parameterization of power in terms of genotype relative
risk can be misleading because the same RRBb operating
in common disease implies a much higher proportion of
variance explained by the locus compared to a locus oper-
ating in a less common disease. For example, when the risk
allele has frequency p ¼ 0.2 and effect size RRBb ¼ 1.1, the
locus explains 0.05%, 0.08%, and 0.13% of the variance in
disease liability for a disorder of frequency K ¼ 0.01, 0.05,
and 0.15, respectively. Hence, to detect a locus that ex-
plains the same proportion of variance in liability, much
larger samples are needed for common disorders (Figure 3).
For example, samples of n¼ 4,059 (50% case subjects, 50%
screened control subjects) are needed to detect a locus that
explains 0.5% of the variance in liability for a disorder
lifetime risk K ¼ 0.01 (RRBb ¼ 1.39), compared to samples
of n ¼ 9,181 when the disorder risk is K ¼ 0.15 (RRBb ¼
1.21). Similar arguments have been used to explain that
much larger GWAS samples are needed for MDD compared
to schizophrenia.45
To the best of our knowledge, the impact of the trio
design and use of unscreened control subjects on the
SNP heritability has not yet been addressed, but our power
analyses build upon a rich literature exploring the charac-
teristics of family-based association studies in the pre-
GWAS era. Ferreira et al. showed that the trio-based trans-
mission disequilibrium test (TDT) has less power when an
additional (non-genotyped) sibling is affected compared
to random families with one affected sibling.18 Li et al.,19
Risch and Teng,46 and Risch47 showed that case-control
studies are generally more powerful when case subjects
are from families with an additional affected sibling,
which is in line with our results (Figure 2B compared to
Figure 2A). Teng and Risch found that family-based ap-
proaches have less power than case-unrelated control stra-The Americtegies for families with multiple affected siblings.20 Of
note, our paper focuses on the pseudocontrol trio design,
because this is how the trio design is typically applied in
GWASs; however, the TDT has often been applied for
candidate genes and could yield more power for rare disor-
ders as has been indicated by Laird et al.21 The power to
detect a locus with the use of unscreened control subjects
can readily be calculated with the online power calculator
of Purcell et al.33 or the Quanto software from Gauder-
man.48 Nevertheless, our study adds also to the current
literature on the power to detect a single locus, because
we directly compare pseudocontrol studies to screened
control studies for multiplex families and assortative mat-
ing. As expected, there is overall similarity between conse-
quences of design for the power to detect a single risk
variant and expected SNP heritability, but in this study
we have formalized these expectations and also shown
that such similarity does not hold when considering assor-
tative mating that impacts the estimated SNP heritability
but not in power to detect a single risk variant.
To conclude, we advise against the use of trio designs for
disorders with a polygenic genetic architecture, such as
psychiatric disorders, and we advise careful consideration
when using unscreened control subjects for prevalent dis-
orders, because these designs can result in an underesti-
mated SNP heritability and decreased power to detect an
associated risk allele.Supplemental Data
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